Escalation of Infliximab Maintenance Therapy in Crohnʼs Disease

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost‐effectiveness analysis

“…Although infliximab has proven to be an effective medication for patients with moderate‐to‐severe CD, loss of response to the 5 mg/kg dose is a common occurrence 15, 23, 24 . After drug response is lost, gastroenterologists typically escalate the dose of infliximab to 10 mg/kg and/or reduce the interval of administration.…”

“…Although infliximab has proven to be an effective medication for patients with moderate-to-severe CD, loss of response to the 5 mg ⁄ kg dose is a common occurrence. 15,23,24 After drug response is lost, gastroenterologists typically escalate the dose of infliximab to 10 mg ⁄ kg and ⁄ or reduce the interval of administration. With evidence from a large randomized-controlled trial 6 and recent FDA approval, adalimumab offers an effective and safe option for infliximab failures.…”